Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
mmelvin SaveSavedRemoved 0
Deal Score0
Berlin, March 1, 2023 – The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC…
Read More
